Utama › Karsinoma Sel Skuamosa Kepala dan Leher › Rhode Island
Kajian klinikal Karsinoma Sel Skuamosa Kepala dan Leher di Rhode Island
7 kajian untuk Karsinoma Sel Skuamosa Kepala dan Leher sedang mencari peserta di lokasi di Rhode Island.
Bandar di Rhode Island
Teks kajian rasmi (Bahasa Inggeris)
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site #0132, Providence
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06788990Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- Smilow Cancer Hospital Care Center - Westerly, Westerly
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT02734537Head and Neck Cancer Study Project in the Geriatric Population
- Rhode Island and The Miriam Hospitals, Providence
Mengambil pesertaFasa 3
Umur 65 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT06998069Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Lifespan Cancer Institute at Rhode Island Hospital /ID# 225705, Providence
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Jun 2026 · NCT04777994A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Women & Infants Hospital, Providence
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Nov 2025 · NCT05902988A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- Rhode Island Hospital, Providence
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Okt 2025 · NCT06699212Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Rhode Island Hospital, Providence
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Ogo 2025 · NCT04429542Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.